

**Food and Drug Administration  
Center for Drug Evaluation and Research**

**Pediatric Subcommittee  
of the Oncologic Drugs Advisory Committee**

Hyatt Regency, One Metro Center, Bethesda, Maryland

**Agenda**

**September 12, 2000**

- |      |   |  |
|------|---|--|
| 1:00 | Call to Order and Opening Remarks   | Victor Santana, M.D.<br>Chair, Pediatric Subcommittee of ODAC        |
|      | Introduction of Committee   |  |
|      | Conflict of Interest Statement  | Karen M. Templeton-Somers, Ph.D.<br>Executive Secretary, ODAC        |
| 1:15 | Open Public Hearing ( <i>60 minutes allocated unless public participation does not last that long</i> ) |  |
| 2:15 | Introduction to the Issues  | Steven Hirschfeld, M.D., Ph.D.<br>Division of Oncology Drug Products |
| 2:30 | Perspective on using expression arrays for tumor diagnosis and classification                           | Todd Golub, M.D., Ph.D.<br>Whitehead/MIT Center for Genome Research  |
| 2:45 | Perspective on using cytogenetics for tumor diagnosis and classification                                | Michelle LeBeau, Ph.D.<br>University of Chicago                      |
| 3:00 | Perspective on using histology for tumor diagnosis and classification                                   | David Parham, M.D.<br>University of Arkansas                         |
| 3:30 | Special challenges in the classification of brain tumors  | Peter Burger, M.D., Ph.D.<br>Johns Hopkins University                |
| 3:45 | Break   |  |
| 4:00 | Perspective on the Use and Development of Chemotherapy in Pediatric Oncology                            | Frank Balis, M.D.<br>National Cancer Institute                       |
| 4:15 | Charge to the Committee<br>Committee Discussion of the Questions  | Steven Hirschfeld, M.D., Ph.D.                                       |
| 5:30 | Adjourn   |  |